Medicina
Departament
University of Sydney
Sídney, AustraliaPublicacions en col·laboració amb investigadors/es de University of Sydney (15)
2023
-
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1992-1998
2022
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
2021
-
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Annals of Oncology, Vol. 32, Núm. 7, pp. 881-895
2020
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
-
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020
Emerging Infectious Diseases, Vol. 26, Núm. 11, pp. 2709-2712
2019
-
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)
Nature Communications
-
Shared heritability and functional enrichment across six solid cancers
Nature Communications, Vol. 10, Núm. 1
-
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
International Journal of Infectious Diseases, Vol. 83, pp. 72-76
2018
-
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Annals of Oncology, Vol. 29, pp. ix164
-
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092
2017
-
Composing a new song for trials: The Standardized Outcomes in Nephrology (SONG) initiative
Nephrology Dialysis Transplantation, Vol. 32, Núm. 12, pp. 1963-1966
2016
-
The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer
Journal of Thoracic Oncology, Vol. 11, Núm. 1, pp. 39-51
2015
-
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types
Journal of the National Cancer Institute, Vol. 107, Núm. 12
1998
-
Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis
Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Núm. 11, pp. 6337-6342